A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression-Reference-Cited by-同舟云学术

A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression

Published:2020-06 Issue: Volume:271 Page:91-99
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Dinoff Adam,Lynch Sean T.,Sekhri Nitin,Klepacz Lidia

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference86 articles.

1. High dose of buprenorphine in the treatment of refractory major depression with severe suicidal tendencies;Ahmadi;J. Addict. Depend.,2017

2. Treatment resistant depression: a multi-scale, systems biology approach;Akil;Neurosci. Biobehav. Rev.,2018

3. Treatment-resistant depression: therapeutic trends, challenges, and future directions;Al-Harbi;Patient Prefer Adherence,2012

4. Depression and pain comorbidity: a literature review;Bair;Arch. Intern Med.,2003

5. Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex;Berger;Br. J. Pharmacol.,2006

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023;Current Psychiatry Reports;2024-02-22

2. A synopsis of multitarget therapeutic effects of anesthetics on depression;European Journal of Pharmacology;2023-10

3. A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult;Drugs & Aging;2023-08-18

4. The efficacy and safety of buprenorphine for the treatment of depression: A systematic review and meta-analysis;Journal of Psychiatric Research;2023-05

5. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents;World Psychiatry;2023-01-14